Early-onset parkinsonism in PPP2R5D-related neurodevelopmental disorder.
Neurodevelopmental disorder
PPP2R5D
Parkinson's disease
Parkinsonism
Journal
European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
10
2020
revised:
16
11
2020
accepted:
11
12
2020
pubmed:
19
12
2020
medline:
9
6
2021
entrez:
18
12
2020
Statut:
ppublish
Résumé
PPP2R5D-related neurodevelopmental disorder (NDD) is a rare autosomal-dominant disease with developmental delay and mild to severe intellectual disability. So far, fewer than 30 affected individuals with mostly recurrent, de novo missense variants in PPP2R5D were reported. Recently, parkinsonism with an onset between 20 and 40 years was reported in four adult individuals with the same p.(Glu200Lys) variant in PPP2R5D. By trio exome sequencing we now identified the variant p.(Glu198Lys) in a 29 year old woman presenting with typical clinical manifestations of PPP2R5D-related neurodevelopmental disorder and additionally with motor decline and levodopa responsive, early-onset parkinsonism from her mid-twenties on. Accordingly, a clear reduction of dopamine transporter in the striatum on both sides was revealed by brain scintigraphy. Our findings further expand the molecular and clinical spectrum of PPP2R5D-related NDD and confirm the association with parkinsonism in early adulthood. This has marked implications for prognosis of PPP2R5D-related NDDs and for the therapeutic management of motor decline and parkinson-like symptoms in affected individuals.
Identifiants
pubmed: 33338668
pii: S1769-7212(20)30833-8
doi: 10.1016/j.ejmg.2020.104123
pii:
doi:
Substances chimiques
Antiparkinson Agents
0
PPP2R5D protein, human
0
Levodopa
46627O600J
Protein Phosphatase 2
EC 3.1.3.16
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104123Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.